1 recruiting, 1 unknown. 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Recruiting 1, Unknown 1 |
Follow Advenchen Laboratories, LLC: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase III Trial of Anlotinib, Catequentinib in Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma (APROMISS) AL3818, Dacarbazine, AL3818 or placebo - Alveolar Soft Part Sarcoma, Leiomyosarcoma | Phase 3 | Recruiting | Advenchen Laboratories, LLC | 325 | 2017-08-15 | 2026-02-25 |
| Phase 1/2a/3 Evaluation of Adding AL3818 to Standard Platinum-Based Chemotherapy in Subjects With Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma (AL3818-US-002) AL3818, Paclitaxel, Pegylated Liposomal Doxorubicin (PLD) - Endometrial Carcinoma, Ovarian Carcinoma | Phase 3 | Unknown | Advenchen Laboratories, LLC | 294 | 2015-12-01 | 2023-11-08 |
Endometrial Neoplasms (1) · Fallopian Tube Neoplasms (1) · Leiomyosarcoma (1) · Ovarian Neoplasms (1) · Sarcoma (1) · Sarcoma, Alveolar Soft Part (1) · Sarcoma, Synovial (1) · Uterine Cervical Neoplasms (1)
anlotinib (2) · Carboplatin (1) · Dacarbazine (1) · Digoxin (1) · Midazolam (1) · Paclitaxel (1) · Rosuvastatin Calcium (1) · Tablets (1) · Topotecan (1) · liposomal doxorubicin (1)
China (2) · Italy (2) · Spain (2) · United Kingdom (2) · United States (2) · South Korea (1)